SCHEMBL4886942

SCHEMBL4886942

Cc1cc(C)cc(-c2ccc(OCC[N+](C)(C)C)c(C=CC(=O)c3ccccc3N)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
ABCB1 P08183 1/20 0.36
MAOB P27338 1/20 0.36
AR P10275 2/20 0.36
SYK P43405 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TNFRSF1A P19438 3/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
ALOX12 P18054 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886938 1.00 MAPT (0.39) MAPTABCB1MAOBARSYK
SCHEMBL14306899 0.89 AR (0.47) MAPTABCB1MAOBARSMN1; SMN2
SCHEMBL14280886 0.86 SYK (0.43) MAPTABCB1MAOBARSYK
SCHEMBL4852423 0.86 SYK (0.43) MAPTABCB1MAOBARSYK
SCHEMBL4881621 0.85 PTPN1 (0.44) TNFRSF1ARELACYP3A4
SCHEMBL4881624 0.85 PTPN1 (0.44) TNFRSF1ARELACYP3A4
SCHEMBL4884102 0.79 PDE4A (0.46) MAPTSMN1; SMN2MAPK1TNFRSF1AMEN1
SCHEMBL4884108 0.79 PDE4A (0.46) MAPTSMN1; SMN2MAPK1TNFRSF1AMEN1
SCHEMBL14280893 0.79 PDE4A (0.45) MAPTSMN1; SMN2MAPK1TNFRSF1AMEN1
SCHEMBL4849810 0.77 ABCB1 (0.43) ABCB1MAOBARSYKSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080027075-A1 Quaternary Amino-Function Chalcones LICA PHARMACEUTICALS A/S (DK) 2008-01-31 US claimed
EP-1682486-A1 QUATERNARY AMINO-FUNCTIONAL CHALCONES Lica Pharmaceuticals A/S (DK) 2006-07-26 EP claimed
WO-2005042467-A1 QUATERNARY AMINO-FUNCTIONAL CHALCONES LICA PHARMACEUTICALS A/S (DK) 2005-05-12 WO claimed
US-20080027075-A1 Quaternary Amino-Function Chalcones LICA PHARMACEUTICALS A/S (DK) 2008-01-31 US disclosed
EP-1682486-A1 QUATERNARY AMINO-FUNCTIONAL CHALCONES Lica Pharmaceuticals A/S (DK) 2006-07-26 EP disclosed
WO-2005042467-A1 QUATERNARY AMINO-FUNCTIONAL CHALCONES LICA PHARMACEUTICALS A/S (DK) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027075-A1 Quaternary Amino-Function Chalcones NR2E1, BET1, NR0B1 MAPT 4666/4885ABCB1 1518/4885MAOB 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.